Angelica Peebles

Pharma reporter at CNBC | Past: Biotech at Bloomberg | Formerly LaVito | Opinions my own

[Angelica Peebles @angelicapeebles]

👀👀

[Angelica Peebles @angelicapeebles]

Another biotech IPO on the horizon...this time Scribe Therapeutics (gene editing company partnered with Lilly), which filed to go public under the ticker $SCTX

https://t.co/sPIoqSTCeG

[STAT @statnews]

Bluebird Bio was a dark biotech morality tale when David Meek bought it. He says the new company, Genetix, is already making money. https://t.co/5wN6TC6xT5

[Angelica Peebles @angelicapeebles]

It's July 1, which means millions of seniors are newly eligible for GLP-1s for obesity. More on who qualifies and what to expect from @annikakimc
https://t.co/jcJc6bPz1B

[Angelica Peebles @angelicapeebles]

Anthropic says it's getting into the drug development business (?). The company will focus on discovering drugs for "neglected" diseases. TBD what it'll do if it finds any promising drug candidates https://t.co/ly7WKHMUsh

[Madison Muller @g0ingmad]

For years, Eli Lilly lived in the shadow of bigger rivals. Then weight-loss drugs changed everything.

For the July cover of @BW, @BradStone and I chronicled one of the most dramatic transformations in the drug industry’s history.

[Angelica Peebles @angelicapeebles]

Incredible details in this @g0ingmad classic

[Bloomberg @business]

Weight-loss drugs turned Eli Lilly into a $1 trillion pharmaceutical giant. Now Dave Ricks needs to prove the boom can last.

Read The Big Take ⤵️ https://t.co/tK09Tsv8r7

[Max Bayer @maxonwifi]

This is a resounding rebuke of the initial refuse to file letter issued by @VPrasadMDMPH earlier this year.

[Max Bayer @maxonwifi]

With new data, Takeda bolsters the case of its submitted orexin program ahead of Q3 PDUFA.

https://t.co/Ue6vqrkFMx

[Kyle LaHucik @ky_lahucik]

spoke w/Parabilis Medicines CEO about the biotech's record-breaking IPO

"People do ask sometimes about the SpaceX IPO and whether it would draw capital away from the biotech industry. I don’t think so. We’re going for our own moonshot right now."

$PBLS

https://t.co/1RNnn6Cg8d

[Angelica Peebles @angelicapeebles]

On Medicare: Novo plans to pitch seniors on the proven health benefits of Wegovy. Lilly plans to emphasize the convenience of Foundayo. Ricks says it will be important to prove this program is cost effective.

[Angelica Peebles @angelicapeebles]

I had a chance to talk to Lilly CEO Dave Ricks and Novo Nordisk CEO Mike Doustdar this weekend at ADA. The big themes: GLP-1 pills and Medicare coverage of obesity drugs in just a few weeks (yes, it's already almost July)

Full story here: https://t.co/XXcQEaHj2u

[Angelica Peebles @angelicapeebles]

On the pills: Novo surpassed 3M scripts of the Wegovy pill, but investors don't seem to care. What's it going to take to change their minds? Time, Doustdar says. What about Foundayo? Prescriptions are "markedly higher" than the 20K figure Ricks shared with us about six weeks ago.

[Andrew Dunn @AndrewE_Dunn]

NEW: Here are biopharma's top-paid CEOs of 2025, taking in pay packages worth over $25M

Median biopharma CEO pay for 2025 came in at $5.35M, up 13% from last year.

The best-paid made far more & we have the receipts
https://t.co/CBHCjCien5

[Bloomberg @business]

The race for no. 3 in obesity drugs just got tougher. https://t.co/13FOZBQvIs

[Madison Muller @g0ingmad]

NEW: Pfizer is pulling back the curtain on its obesity ambitions, releasing new data on an experimental weight-loss shot & outlining a strategy to claw its way into a leadership position in a market dominated by those with first-mover advantages.
🎁🔗https://t.co/oaXLVn278d

[Zach Brennan @ZacharyBrennan]

Scoop: acting FDA commissioner Kyle Diamantas told rare disease nonprofits yesterday that some major changes are coming in the post-Makary era: No more career staff overrules, and expect more adcomms https://t.co/VdA5kZAotF

[Angelica Peebles @angelicapeebles]

A nice look from @annikakimc at how some of the World Cup host cities are preparing for infectious disease risks https://t.co/wgxVXUPL1w

[Adam Feuerstein ✡️ @adamfeuerstein]

Read here:

Does Revolution Medicines’ $RVMD pancreatic cancer drug have even greater potential? Rick Pazdur has ideas on how to find out

https://t.co/P7BIWd6UuR

[Angelica Peebles @angelicapeebles]

Another day, another Lilly deal. What’s going on over there? Lilly’s willing to pay more for “real medicines” and it’s looking beyond its four main therapeutic areas https://t.co/Uir1sTmuMj